{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:49:41Z","timestamp":1785296981576,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"am","delay-in-days":304,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive"},{"DOI":"10.13039\/100006436","name":"Celgene international II Switzerland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejca.2020.05.018","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T23:26:14Z","timestamp":1593645974000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Canc\u00e9rologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)"],"prefix":"10.1016","volume":"136","author":[{"given":"Yves","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Pointet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Khemissa Akouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidaut","family":"Wahiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Louafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gratet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Miglianico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bouhier Leporrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thirot Bidault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Texereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Terrebonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Gouttebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Barriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gigout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lepere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Despax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Chamois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Artignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Lesouef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bengrine Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mme E.","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Dreanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brezault-Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Holllebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gildas","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Chauvenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Moryoussef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Biondiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Avisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Parzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Codoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Pripon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Atlassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Cojocarasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Suc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bedjaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Houyau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Gargot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Henneresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lavau denes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lebrun Lyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Genet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pr Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Escande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.05.018_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Canc"},{"issue":"6","key":"10.1016\/j.ejca.2020.05.018_bib2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFORINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2020.05.018_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.05.018_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2020.05.018_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12999","article-title":"Nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial","volume":"14","author":"Young","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.05.018_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12885-018-5244-2","article-title":"NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer","volume":"19","author":"Blomstrand","year":"2019","journal-title":"BMC Canc"},{"issue":"7","key":"10.1016\/j.ejca.2020.05.018_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4251\/wjgo.v9.i7.281","article-title":"Evolving treatment landscape for early and advanced pancreatic cancer","volume":"9","author":"Lau","year":"2017","journal-title":"World J Gastrointest Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2020.05.018_bib9","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"ESMO guidelines committee. Cancer of the pancreas: ESMO clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/annonc\/mdl427","article-title":"FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, foradvanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study","volume":"18","author":"Taieb","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib11","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2005.17.749","article-title":"Systemic therapy for metastatic colorectal cancer: current options, current evidence","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib12","first-page":"1687","article-title":"Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9\/CEA)","volume":"25","author":"Klapdor","year":"2005","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.ejca.2020.05.018_bib13","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/j.ejca.2014.09.015","article-title":"Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)","volume":"50","author":"Trouilloud","year":"2014","journal-title":"Eur J Canc"},{"issue":"5","key":"10.1016\/j.ejca.2020.05.018_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125350","article-title":"F. Sequential FOLFIRI.3+gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"10","author":"Anota","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2020.05.018_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer Institute of the United States, national cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.05.018_bib16","unstructured":"Common Terminology criteria for adverse events v4.0 (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcae_4_with_lay_terms.pdf."},{"key":"10.1016\/j.ejca.2020.05.018_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.05.018_bib18","unstructured":"Bakoyannis G. and Tououmi G. Statistical methods in medical research, http:\/\/smm.sagepub.com\/content\/early\/2011\/01\/04\/0962280210394479. May 16, 2012."},{"issue":"5","key":"10.1016\/j.ejca.2020.05.018_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clinre.2011.02.002","article-title":"Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine","volume":"35","author":"Trouilloud","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ejca.2020.05.018_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919850367","article-title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review","volume":"11","author":"Chiorean","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.05.018_bib21","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/annonc\/mdx503","article-title":"Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?","volume":"28","author":"Sahin","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.05.018_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2020.05.018_bib23","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2020.05.018_bib24","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2020.05.018_bib25","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2020.05.018_bib26","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2020.05.018_bib27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2020.05.018_bib28","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.2013.51.0826","article-title":"Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity","volume":"31","author":"Poplin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib29","article-title":"Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study","author":"Van Cutsem","year":"2016","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.018_bib30","article-title":"FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35-PANOPTIMOX)","author":"Laetitia","year":"2018","journal-title":"ASCO presentation"},{"issue":"NO. 1","key":"10.1016\/j.ejca.2020.05.018_bib31","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2017-0338","article-title":"HALO-109\u2013301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer","volume":"14","author":"Doherty","year":"2017","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.05.018_bib33","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/fon-2018-0903","article-title":"A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine","volume":"15","author":"Sonbol","year":"2019","journal-title":"Future Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2020.05.018_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS471","article-title":"Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)","volume":"37","author":"Hammel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2020.05.018_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4107","article-title":"Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): a randomized phase II study (PRODIGE 37-FIRGEMAX)","volume":"36","author":"Taieb","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:36Z","timestamp":1760732856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S0959804920302859"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Canc\u00e9rologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}